Menu
Recruiting NCT06314204

Impact of Cannabis Consumption on the Course, Modalities of Hospitalization and the Short-term Prognosis of Inpatients Suffering From Psychotic Symptoms

— Observational Psychotic; Disorder, Cannabis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Psychotic; Disorder, Cannabis. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Impact of Cannabis Consumption on the Course, Modalities of Hospitalization and the Short-term Prognosis of Inpatients Suffering From Psychotic Symptoms : Multicenter Comparative Observational Study

Overview

Few studies have evaluated, in patients with symptomatology the impact of cannabis use on the duration of hospitalization and on short- and medium-term developments. The objective of this study will be to assess the impact of cannabis on the duration, the hospitalization and the short- and medium-term evolution of patients with psychotic symptoms and cannabis use. We hypothesize that these patients (in comparison with patients with psychotic symptomatology and not using cannabis) would be hospitalized more long, exposed to a higher risk of resistance to the usual therapeutics, would have a lack of therapeutic alliance and insight, relapses and hospitalizations more frequent, more marked negative symptoms and lower quality remission. They would also be more prone to impulsive and aggressive behaviour.

Detailed description

Several studies have reported that cannabis use worsen the prognosis of psychiatric pathologies in general and psychotic in particular.

Few or no studies have evaluated the impact of cannabis consumption on patients with psychotic symptoms during their hospitalization (duration, type of hospitalization, quality of relationship with staff hospital), and on the short-term prognosis.

The objective of this study will be to assess the impact of cannabis on the duration of the hospitalization and the short- and medium-term evolution of patients with a psychotic symptomatology and cannabis use. Making the hypothesis that these patients (compared to patients with symptomatology psychotic and not using cannabis) would be hospitalized longer, exposed at a higher risk of resistance to the usual therapies, to have a lack of alliance therapeutic and insight, relapses and more frequent hospitalizations and symptoms.

They would also be more likely to have lower quality. They would also be more likely to be impulsive, and have aggressive behaviours.

Primary outcome measures

  • PANSS: Positive and Negative Syndrom Scale [Time frame: AT the beginning of the study, before any procedure, (T1)]
  • PANSS: Positive and Negative Syndrom Scale [Time frame: Approximatively 2 or 3 weeks after T1,On the day of the discharge (T2)]
  • PANSS: Positive and Negative Syndrom Scale [Time frame: 1 month after the discharge (T3)]
  • PANSS: Positive and Negative Syndrom Scale [Time frame: 3 month after the discharge (T4)]
  • MCQ-SF :Marijuana Craving Questionnaire- Short Form [Time frame: AT the beginning of the study, before any procedure (T1)]
  • MCQ-SF :Marijuana Craving Questionnaire- Short Form) [Time frame: Approximatively 2 or 3 weeks after T1 ,On the day of the discharge (T2)]
  • MCQ-SF :Marijuana Craving Questionnaire- Short Form) [Time frame: one month after the discharge]
  • MCQ-SF :Marijuana Craving Questionnaire- Short Form) [Time frame: three month after the discharge]
  • CGI: Clinical Global Impression [Time frame: AT the beginning of the study, before any procedure (T1)]
  • CGI: Clinical Global Impression [Time frame: Approximatively 2 or 3 weeks after T1 ,On the day of the discharge (T2)]

Eligibility criteria

Inclusion criteria

  • Hospitalized in psychiatry regardless of the mode of hospitalization
  • With or without protective measures (guardianship or curatorship)
  • Presenting psychotic symptoms (schizophrenia, schizo affective disorder, thymic disorder with psychotic characteristic, psychotic disorder substance-induced, brief psychotic disorder, schizophrenic disorders, delirious disorders)
  • Members of the social security system
  • Enlightened information

Exclusion criteria

  • Degenerative neurological pathologies or mental retardation
  • Psychotic disorders secondary to generalized medical conditions(epilepsy, delirium tremens, tumors, etc.)
  • Other psychiatric pathologies

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Other

Study locations

France · 1 center
  • unité de recherche clinique de l'E.P.S de Ville Evrard — Neuilly-sur-Marne

Identifiers

NCT: NCT06314204 · 2015-A01222-47

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗